Y
Yowell Rl
Researcher at University of Utah
Publications - 32
Citations - 1171
Yowell Rl is an academic researcher from University of Utah. The author has contributed to research in topics: Transplantation & Heart transplantation. The author has an hindex of 18, co-authored 32 publications receiving 1161 citations. Previous affiliations of Yowell Rl include LDS Hospital & Veterans Health Administration.
Papers
More filters
Journal Article
Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications.
Elizabeth H. Hammond,Yowell Rl,Nunoda S,Ronald L. Menlove,Dale G. Renlund,Michael R. Bristow,Kent W. Jones,John B. O'Connell +7 more
TL;DR: It is concluded that immunofluorescence should be routinely done on all heart biopsies for the first month after transplantation, because patients with vascular (humoral) rejection cannot be reliably identified by any other means.
Journal Article
Vascular rejection and its relationship to allograft coronary artery disease.
Elizabeth H. Hammond,Yowell Rl,Price Gd,Ronald L. Menlove,Olsen Sl,John B. O'Connell,Michael R. Bristow,Donald B. Doty,Roger C. Millar,Shreekanth V. Karwande +9 more
TL;DR: A significant difference in the time to the development of allograft coronary artery disease based on the rejection pattern was found, whether or not patients sensitized to OKT3 were excluded from evaluation.
Journal ArticleDOI
Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection.
TL;DR: This entire issue of the Journal of Heart and Lung Transplantation is devoted to the potential etiologic factors as well as the clinical manifestations of ACAD.
Journal Article
Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations.
Olsen Sl,Lynne E. Wagoner,Elizabeth H. Hammond,David O. Taylor,Yowell Rl,Ensley Rd,Michael R. Bristow,John B. O'Connell,Dale G. Renlund +8 more
TL;DR: The addition of cyclophosphamide and plasmapheresis may improve the outcome of vascular rejection, but the results of treatment with currently available treatment modalities remain unacceptably poor.